Regeneron Pharmaceuticals Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $2.95B | $7.82B | $811.8M |
| Jun 2017 | $2.59B | $8.11B | $744.3M |
| Sep 2017 | $2.65B | $8.70B | $792.1M |
| Dec 2017 | $2.62B | $8.76B | $812.7M |
| Mar 2018 | $2.81B | $9.37B | $1.02B |
| Jun 2018 | $2.77B | $9.95B | $917.9M |
| Sep 2018 | $2.94B | $10.81B | $1.09B |
| Dec 2018 | $2.98B | $11.73B | $1.47B |
| Mar 2019 | $3.41B | $12.85B | $1.71B |
| Jun 2019 | $3.42B | $13.17B | $1.05B |
| Sep 2019 | $3.43B | $13.94B | $1.38B |
| Dec 2019 | $3.72B | $14.81B | $1.62B |
| Mar 2020 | $3.62B | $15.76B | $2.21B |
| Jun 2020 | $5.37B | $14.43B | $1.99B |
| Sep 2020 | $5.96B | $16.08B | $1.57B |
| Dec 2020 | $6.14B | $17.16B | $2.19B |
| Mar 2021 | $5.80B | $17.77B | $1.44B |
| Jun 2021 | $6.36B | $21.49B | $2.07B |
| Sep 2021 | $6.41B | $23.67B | $3.43B |
| Dec 2021 | $6.67B | $25.43B | $2.89B |
| Mar 2022 | $6.43B | $26.35B | $3.35B |
| Jun 2022 | $6.52B | $27.21B | $3.40B |
| Sep 2022 | $6.24B | $27.68B | $3.49B |
| Dec 2022 | $6.55B | $29.21B | $3.11B |
| Mar 2023 | $6.56B | $30.06B | $3.92B |
| Jun 2023 | $6.64B | $30.66B | $1.94B |
| Sep 2023 | $7.26B | $32.16B | $2.15B |
| Dec 2023 | $7.11B | $33.08B | $2.73B |
| Mar 2024 | $7.38B | $34.37B | $2.60B |
| Jun 2024 | $7.88B | $36.09B | $1.92B |
| Sep 2024 | $8.12B | $37.44B | $2.01B |
| Dec 2024 | $8.41B | $37.76B | $2.49B |
| Mar 2025 | $8.16B | $37.55B | $3.09B |
| Jun 2025 | $8.28B | $38.22B | $2.00B |
| Sep 2025 | $9.21B | $40.17B | $2.51B |
| Dec 2025 | $9.30B | $40.56B | $3.12B |
| Mar 2026 | $9.45B | $40.87B | $2.96B |
| Jun 2026 | $10.02B | $41.73B | $2.46B |